

Message

**From:** juergen.sigg@novartis.com [juergen.sigg@novartis.com]  
**Sent:** 5/11/2009 6:08:51 AM  
**To:** [REDACTED]@vetter-pharma.com]  
**CC:** [REDACTED]@vetter-pharma.com]; [REDACTED]@vetter-pharma.com]; [REDACTED]  
[REDACTED]@vetter-pharma.com]; Christophe Royer ["cn=christophe royer/ou=ph/o=novartis@ph"];  
[REDACTED]/ou=ph/o=novartis@ph"]  
**Subject:** Re: Action item

Dear Christine

this action item came out of our discussion on silicone levels to be evaluated. Based on [REDACTED] we have requested to test silicone levels below the [REDACTED], while you argued that this level is already the minimum [REDACTED]  
[REDACTED]

This rational is still required, therefore we should not close the action item. We agreed that the rational will be completed by the results of the silicoinozation studies which hopefully show that the selected silicone level is also the lowest feasible for a robust process in consideration of the [REDACTED] for Lucentis.

Best regards

Jürgen

**Dr. Juergen Sigg**  
**Novartis Pharma AG**  
Novartis Biologics - Process Sciences & Production  
Pharmaceutical Development  
WSJ-340.8.11  
Forum-1  
CH-4056 Basel  
Switzerland  
Phone: +41 61 3243508  
Fax: +41 61 324 74 32  
Email : [juergen.sigg@novartis.com](mailto:juergen.sigg@novartis.com)

Christine Kleber <[christine.kleber@vetter-pharma.com](mailto:christine.kleber@vetter-pharma.com)>

Christine Kleber <christine.kleber@vetter-pharma.com>  09.05.2009 12:13	To	juergen.sigg@novartis.com
	cc	[REDACTED]@vetter-pharma.com>, christophe.royer@novartis.com, K: [REDACTED]@vetter-pharma.com>, [REDACTED]@vetter-pharma.com>
	Subject	Action item

Hi Juergen,  
I'm not sure, what you did expect regarding the following action item.

7	▼	Siliconization Study	First overview of rational regarding established levels of silicone at Vetter	[REDACTED]	15-May-2009	Open
---	---	----------------------	---	------------	-------------	------

Is the explanation given in the development plan sufficient and can we close this action item?  
More details regarding our siliconisation process could follow till end of May.

Kind regards,  
[REDACTED]

-----  
Vetter Pharma-Fertigung GmbH & Co. KG

[REDACTED]  
Process Development & Implementation  
Schützenstrasse 87  
88212 Ravensburg

Phone: +49-751-37 00 -2384  
Fax.: +49-751-37 00 - 4002  
E-Mail: [REDACTED]@vetter-pharma.com  
Internet: www.vetter-pharma.com